两种静脉脂肪乳剂对比研究:SO-ILE早产儿生长与BPD发生率优于SMOF-ILE
Comparison of growth and morbidity outcomes in preterm infants using two different intravenous lipid emulsions
这是一项回顾性队列研究,比较了SO-ILE和SMOF-ILE两种静脉脂肪乳剂在早产儿中的应用效果,发现SO-ILE在36周PMA时身高和头围增长、BPD发生率及尿路感染方面优于SMOF-ILE,但两种制剂在PNAC及其他主要并发症方面无显著差异。研究基于多中心回顾性观察设计,样本量347例,作者强调结果需谨慎解读且需前瞻性研究验证。
Background
Intravenous lipid emulsions (ILE) are an essential component of parenteral nutrition (PN), necessary for the growth and development of infants when enteral nutrition is not possible. Preterm infants are vulnerable to insufficient adipose stores due to their lack of in utero fat accretion that typically occurs during the third trimester, which increases risk of essential fatty acid deficiency (EFAD) due to low reserves of essential fatty acids (EFA). ILEs are comprised primarily of omega-3 and omega-6 fatty acids including linoleic acid (LA) and alpha-linoleic acid (ALA), respectively [1]. LA is further converted to arachidonic acid (AA), whereas ALA is converted to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), all of which are necessary for neurological, immune, and retinal development in preterm infants [2,3,4]. Providing these EFAs is necessary to prevent EFAD, which can occur within 72 h of inadequate lipid intake in premature and very low birth weight (VLBW) infants [1, 4].
Since its FDA approval for use in neonates in 1981, 100% soybean-oil based ILE (SO-ILE), has been the primary source of ILE for preterm infants across the United States until recently [5]. For many years, SO-ILE was the only available option, and conferred benefits such as the provision of essential LA and ALA. However, SO-ILE lacks the critical byproducts EPA and DHA (Supplementary Table 1) [6]. At the current recommended goal dose of 3 grams per kilogram (kg) per day, SO-ILEs have been linked to an increased risk of parenteral nutrition-associated cholestasis (PNAC) [7]. Potential mechanisms for the liver injury include low concentration of antioxidants, high concentration of omega-6 fatty acids leading to increased prostaglandins and proinflammatory leukotrienes, and lack of DHA and EPA [8]. Furthermore, SO-ILE contains a high content of phytosterols, which can impair immune function, generate a proinflammatory response, and interfere with bile acid secretion [9].
Over the past few decades, research has been underway with the goal of identifying an ILE option for neonates with more benefit and fewer complications. One of the options is a mixed component ILE consisting of Soybean oil, Medium chain triglycerides (MCTs), Olive oil, and Fish oil (SMOF). This was recently approved by the FDA for use in neonates in 2022 [10]. The mixed component ILEs such as SMOF are less susceptible to lipid peroxidation, and thus are associated with reduced systemic inflammatory response and positive effects on leukocyte and reticuloendothelial function [11]. The monosaturated fatty acid content of olive oil helps to prevent cellular damage, provide hepatic protection, and decrease lipid peroxidation [12]. SMOF-ILE also contains a higher amount of antioxidant vitamin E and less phytosterols than SO-ILE, bolstering its potential hepatoprotective properties [6, 13]. Therefore, to prevent development or worsening of PNAC, some institutions will transition ILE therapy from SO-ILE to SMOF-ILE or may offer SMOF-ILE as the primary ILE. Although the addition of omega-3 FA in SMOF-ILE has perceived benefits over SO-ILE at preventing PNAC, studies have shown inconsistent findings for prevention of PNAC between SO-ILE and SMOF-ILE [6, 14].
Furthermore, SMOF-ILE has a higher omega-3 content compared to SO-ILE, providing more DHA and EPA (Supplementary Table 1) [11]. The higher omega-3 content may offer potential benefits for brain and retina development, along with anti-inflammatory effects that could reduce comorbidities associated with prematurity [15,16,17,18]. Despite the presence of DHA in SMOF-ILE, neither ILE prevents the postnatal decline in DHA in preterm infants. In addition, although SMOF-ILE increases DHA and EPA levels, this leads to a further decrease in AA and a decreased AA:DHA ratio compared with the ratio observed in utero [19,20,21]. This further decline seen with SMOF-ILE is significant because, although DHA has benefits, AA also plays a crucial role in immune function, brain and retina development, and tissue and bone formation in preterm infants [22]. These concomitant changes in AA and EPA levels with increased omega-3 delivery are important considerations given their unique bioactive roles in human physiology [20, 21, 23]. Moreover, the few studies that compared growth outcomes between these two ILEs, had inconsistent findings, prompting the need for further investigation [24,25,26,27]. Given the limited data and inconsistent conclusions comparing these two ILEs, we aimed to evaluate differences in growth and morbidities in preterm infants receiving SO-ILE or SMOF-ILE.
Methods
This was a multicenter, retrospective cohort study conducted at two academic neonatal intensive care units (NICUs): a level IV NICU at Rainbow Babies & Children’s Hospital (RBC) and a level III NICU at NYU Langone Hospital – Long Island (NYU-LI). Eligible infants were born between January 2015 and July 2024 (RBC) or January 2018 and December 2023 (NYU-LI). Inclusion criteria were admission to the NICU within 24 h of life, gestational age ≤32 weeks, birth weight ≤1500 g, and receipt of SO-ILE or SMOF-ILE for ≥7 consecutive days. Exclusion criteria included congenital anomalies, inborn errors of metabolism, intestinal failure, birth at an outside hospital, death within 7 days of life, or receipt of both ILE formulations during the hospital course.
The primary objective of this study was to assess growth outcomes in infants receiving SMOF-ILE compared to SO-ILE for at least seven days, characterized by changes in weight, length, and head circumference (HC) z-scores from birth to one month of life and one month to 36 weeks’ postmenstrual age (PMA) or at discharge, whichever came first. The z-scores were generated or calculated using the 2013 Fenton growth chart for preterm infants [28]. The secondary objectives were to compare the incidence of PNAC, bronchopulmonary dysplasia (BPD), hypertriglyceridemia (HTG), late-onset sepsis (LOS), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP), spontaneous intestinal perforation (SIP), intraventricular hemorrhage (IVH), and mortality. We defined the following: PNAC as direct bilirubin >2 mg/dL or >50% of total bilirubin on two consecutive measurements; BPD as any grade (1–3) based on the NRN 2019 criteria at 36 weeks’ PMA; hypertriglyceridemia (HTG) as triglyceride ≥250 mg/dL; LOS as positive culture for blood, cerebrospinal fluid (CSF), urine after day 7 of age; NEC as Bell stage II or higher; ROP as stage ≥3 or requiring intervention, and IVH as any grade I–IV [29,30,31,32,33,34].
The study protocol was reviewed and approved as exempt by the institutional review boards of both participating institutions – NYU IRB protocol s24-00105 and RBC protocol STUDY20241092. Given the retrospective observational design and use of de-identified data, the requirement for informed consent was waived.
Statistical analysis
For baseline characteristic data, normally distributed continuous data were compared for mean equality between the two groups using independent samples Student’s t tests, while categorical data were assessed for distributional equality using Pearson’s chi-square tests. Severity comparison was analyzed using the Kendall’s Tau test for ordinal data. Analyses of anthropometric z-score changes (primary outcomes) were performed using complete data for each interval; infants missing anthropometric measurements at a corresponding time point were excluded from that specific interval analysis. The primary outcomes were analyzed using repeated measures ANOVA to estimate the study group effect on the outcomes over time. Significant (p < 0.10) interaction between the study group and post-baseline time point required separate comparisons at each time point. Hence, independent Student’s t tests were performed to compare the mean difference in study groups for the change from baseline to 1 month and the change from 1 month to 36 weeks. Separate, fixed effect ANOVA modeling was performed at each post-baseline time point with effects for treatment, center, and their interaction and those yielded insignificant interaction p-values (p > 0.10). Hence, data were aggregated across our two study centers for analysis as no significant enhancement/reduction of the treatment effect occurred based on the center giving the treatment. Multivariable regression analyses were performed for both primary and significant secondary outcomes. For the primary outcomes, models were adjusted for gestational age, sex, intrauterine growth restriction (IUGR), antenatal steroid exposure, length of stay, 5-min Apgar score, and average daily total lipid dose received (g/kg), with SMOF-ILE as the exposure of interest. For BPD and urinary tract infections (UTI), multivariable models were adjusted only for 5-min Apgar score and average daily total lipid dose received (g/kg), given the study’s limited sample size and to minimize model overfitting. Statistical analyses were performed using IBM SPSS Statistics (version 25.0). A p-value < 0.05 via two-sided testing was considered statistically significant unless otherwise noted.
Results
A total of 625 infants who met gestational age and birth weight criteria were reviewed during the study period. A total of 278 infants were excluded due to congenital anomalies, receipt of either SMOF-ILE or SO-ILE for less than seven days, receipt of both SMOF-ILE and SO-ILE within the first seven days of therapy, birth at an outside hospital, or death within the first seven days of life. Therefore, 347 infants met all inclusion criteria with 179 receiving SO-ILE (109 from NYU and 70 from RBC) and 168 receiving SMOF-ILE (97 from NYU and 71 from RBC) (Supplementary Fig. 1).
Baseline demographic comparisons revealed significantly higher mean Apgar scores at both 1 and 5 min in the SMOF-ILE group compared to the SO-ILE group (p = 0.039 and p < 0.001, respectively) (Table 1). Additionally, infants in the SMOF-ILE group received a significantly higher average daily total lipid dose (grams/kilogram/day) compared to SO-ILE (2.56 vs 2.42, respectively, p < 0.001) (Table 1). No other significant differences in baseline characteristics were observed between the two groups.
Primary outcomes
All average changes in z-scores from birth to one month of age were negative across both groups. Infants who received SO-ILE demonstrated significantly greater weight z-score decline from birth to one month compared to those who received SMOF-ILE; the mean change in weight z-score was –0.76 for the SO-ILE group versus –0.59 for the SMOF-ILE group (p = 0.006) (Table 2). However, no significant difference in weight z-score change was observed between the groups from one month to 36 weeks’ PMA (p = 0.24). For length, there was no significant difference in z-score change from birth to one month between the two groups. However, from one month to 36 weeks’ PMA, infants in the SO-ILE group showed a significant improvement in length z-score compared to the SMOF-ILE group (0.13 vs. –0.24; p = 0.002; Table 2). Regarding head circumference, no significant differences in z-score changes were observed between the groups during the intervals from birth to one month or from one month to 36 weeks’ PMA. However, over the full period from birth to 36 weeks’ PMA, the SO-ILE group showed significantly better head circumference growth compared to the SMOF-ILE group. Post hoc analysis for head circumference revealed a mean difference for the SMOF-ILE group of –0.152 (95% CI: –0.28 to –0.02; p = 0.020) from birth to 36 weeks’ PMA (Table 2).
After multivariate regression analysis that included the gestational age, sex, IUGR, antenatal steroid exposure, and length of stay, 5-min Apgar score, and average daily total lipid intake, the SMOF-ILE group did not demonstrate a significantly greater improvement for changes in weight z-score from birth to one month compared to the SO-ILE group (0.106; 95% CI −0.013 to 0.225; p = 0.082) (Table 3). In contrast, SMOF-ILE was associated with significantly worse changes in length z-score from one month to 36 weeks’ PMA or discharge (–0.392; 95% −0.634 to −0.150; p = 0.002) as well as changes in head circumference z-score from birth to 36 weeks’ PMA or discharge (–0.251; 95% CI: –0.480 to −0.022; p = 0.032).
Secondary outcomes
Several secondary outcomes were evaluated (Table 4; Fig. 1a, b). There were no significant differences in rates of PNAC, SIP, ROP, IVH (all grades), and mortality between the two groups. Although not statistically significant, a higher proportion of infants who received SO-ILE developed hypertriglyceridemia compared to those who received SMOF-ILE (19.0% vs. 11.9%, respectively; p = 0.069) and a higher portion of infants who received SMOF-ILE developed NEC compared to those who received SO-ILE (7.7% for SMOF-ILE vs. 3.4% for SO-ILE; p = 0.073). Incidence of late-onset sepsis did not differ significantly between the groups. However, the incidence of urinary tract infection was more common in the SMOF-ILE group (17.3% vs. 8.4%; p = 0.013). The adjusted analysis showed infants receiving SMOF-ILE had higher odds of urinary tract infection compared with those receiving SO-ILE (odds ratio [OR] 1.996; 95% confidence interval [CI], 1.015–3.927; p = 0.045). Additionally, SMOF-ILE administration was associated with a significantly higher rate of BPD compared to SO-ILE (67.3% vs. 50.0%; p = 0.001). The adjusted analysis showed infants receiving SMOF-ILE had higher odds of all types of BPD compared with those receiving SO-ILE (OR 2.337; 95% CI 1.462–3.735; p < 0.001).
A Incidence of BPD and UTI by intravenous lipid emulsion type. Incidence of bronchopulmonary dysplasia (BPD) and urinary tract infection (UTI) among infants receiving soybean oil–based intravenous lipid emulsion (SO-ILE) compared with mixed lipid emulsion (SMOF-ILE). Asterisks indicate statistically significant between-group differences (*p < 0.01; **p < 0.05). B Incidence of secondary outcomes by intravenous lipid emulsion type. Incidence of secondary outcomes among infants receiving soybean oil–based intravenous lipid emulsion (SO-ILE) compared with mixed lipid emulsion (SMOF-ILE). PNAC Parenteral nutrition–associated cholestasis, SIP spontaneous intestinal perforation, NEC necrotizing enterocolitis, HTG hypertriglyceridemia, LOS late onset sepsis, IVH intraventricular hemorrhage, ROP retinopathy of prematurity. Asterisks indicate statistically significant between-group differences (*p < 0.01; **p < 0.05).
Discussion
In this study population, we found that infants in the SO-ILE group demonstrated significantly better growth by 36 weeks postmenstrual age (PMA) or at discharge, specifically in length and head circumference, compared to those receiving SMOF-ILE. Additionally, the SO-ILE group had a significantly lower incidence of BPD, as well as fewer positive urine cultures. Importantly, there were no significant differences between the two groups regarding complications associated with prolonged ILE exposure, such as PNAC or HTG.
Growth outcomes
Assessing change in z-score confers the benefit of considering changes over time, rather than comparing static measurements of infants to fixed percentiles [35]. We strategically chose two distinct points of measure from birth to 1 month, and from 1 month to 36 weeks PMA or discharge, whichever came first. An international, multicenter cohort study showed that healthy preterm infants consistently adapt within the first 3 weeks of life to a “new” trajectory that is, on average, 0.8 z-scores below their birth weight percentile [36]. Additionally, the majority of ILE provision occurs during the initial weeks of life. Therefore, the birth to 1 month time interval captures growth during the time that infants receive ILE at the highest rate, when outcomes are less affected by enteral nutrition. After this postnatal weight loss and once preterm infants can tolerate adequate nutrition, average preterm infant growth becomes roughly parallel to growth chart curves on their “new” trajectory [35, 36]. Hence, it was decided that a more accurate approach would be to evaluate the change in outcome measurements from birth to 1 month of age and from 1 month of age to 36 weeks PMA or discharge, rather than birth to 36 weeks PMA or discharge.
The findings of this study regarding growth outcomes differ from those reported in earlier studies. In a prospective randomized control trial (RCT) by Abrams et al., there was no difference in growth outcomes with prolonged exposure (≥28 days) of SMOF-ILE or SO-ILE [37]. Costa et al. observed superior head circumference and length growth from birth to 36 weeks PMA or discharge in preterm infants (birth weight ≤1250 g) who received SMOF-ILE compared to SO-ILE [26]. A follow-up study from the same cohort also reported increased cerebellar volume in extremely preterm infants (≤28 weeks gestation and/or ≤1000 g birth weight) receiving SMOF-ILE [38]. However, in these studies by Costa et al., the total lipid intake was higher and duration of parenteral nutrition was longer for both cohorts compared to the present study. Similarly, Bin-Nun et al. found improved head circumference growth in VLBW infants receiving SMOF-ILE [39]. In contrast, a single-center retrospective cohort conducted by Asfour et al., reported no significant difference in change in head circumference z-score from birth to discharge between the two groups, though they did observe improved weight gain at discharge in the SO-ILE group [27]. Furthermore, a study by Al-Mouqdad et al. observed SMOF-ILE to be associated with significant myelination delay, increased extra cerebral space, and cerebellar volume reduction compared to SO-ILE [40]. These findings contradict those of Costa et al., particularly regarding cerebellar volume. Lastly, a single-center observational study by Caruggi et al. compared brain MRI findings at term-equivalent age and neurodevelopmental outcomes at 2 years between infants receiving SO-ILE and SMOF-ILE and found no significant differences between the groups [41]. These findings further highlight the inconsistent results reported in the current literature regarding the impact of different lipid emulsions on growth and neurodevelopmental outcomes in preterm infants. Although our multicenter study observed improved linear and head circumference growth in the SO-ILE group, the observational design limits causal inference. Differences among studies may also reflect variations in study design, sample size, patient population, duration of lipid exposure, nutritional practices, and center-specific protocols.
Significant secondary outcomes
Similar to growth outcomes, the findings of this study also differ from prior reports regarding prematurity-related comorbidities. In this cohort, the SMOF-ILE group had higher odds of developing BPD (OR 2.34, 95% CI 1.46–3.74, p < 0.001). This increased BPD risk is consistent with prior mechanistic and clinical evidence. In an animal study, Lavoie et al. demonstrated that SMOF-ILE acted as a pro-oxidant and induced hypo-alveolarization through exaggerated apoptosis, suggesting potential disruption of normal alveolar development [42]. Although Martin et al. demonstrated that lower DHA levels were associated with increased risk of BPD [9], several clinical studies have reported that DHA supplementation is associated with unfavorable pulmonary outcomes. A meta-analysis by Dang et al. found that enteral DHA (with or without AA) did not protect against prematurity-related comorbidities and, in fact, increased BPD risk [43]. Likewise, Wackernagel et al. reported that higher AA levels in the first four weeks of life correlated with greater reduction in BPD severity [44]. A retrospective study by Correani et al., found that infants receiving fish oil-containing emulsion had significantly lower oxygen saturation (SpO2) between 33 and 35 weeks gestation and a worse SpO2 to a fraction of inspired oxygen (FiO2) ratio [45]. However, the current literature regarding the impact of SMOF-ILE on BPD remains inconsistent. Asfour et al., in a retrospective observational study, reported a lower incidence of BPD among infants receiving SMOF-ILE [27]. Similar findings were reported by Chien-Chang Hsiao et al. in an RCT demonstrating reductions in inflammatory markers, shorter duration of ventilatory support, and lower rates of BPD with fish oil–containing lipid emulsions [16]. In contrast, Costa et al., Abrams et al., and Anna Repa et al., all RCTs, found no significant differences in BPD outcomes between SMOF-ILE and SO-ILE [26, 37, 46]. Taken together, these findings suggest ongoing equipoise regarding the pulmonary effects of SMOF-ILE in preterm infants, consistent with the meta-analysis by Kapoor et al., which also demonstrated no significant difference in BPD outcomes between the two lipid formulations [47].
Our study evaluated late onset sepsis defined as positive blood, CSF, and/or urine cultures in the setting of comparing two ILE. Although no significant difference was seen for LOS with a positive blood or CSF cultures, an increased risk for positive urine cultures, i.e a UTI was found for preterm infants receiving SMOF-ILE (OR 1.996, 95% CI 1.015–3.927, p = 0.045). These findings may be secondary to the fact that omega-3 FAs provide an anti-inflammatory response, which can lead to a decreased immune response [48, 49]. Studies have shown that fish oil supplementation, EPA, DHA, and a lower omega-6/omega-3 ratio, reduce the ability of monocytes to induce recruitment of neutrophils and adhesion to endothelial cells [49,50,51]. Martin et al. showed that lower AA levels were associated with late-onset sepsis, which is also consistent with another retrospective study, which found that fish oil-containing lipid emulsion was associated with an increase in LOS [9, 24]. However, the RCT by Abrams et al. found no differences for late-onset sepsis between the two groups [37]. Therefore, our study findings raise the need of further investigation focusing on immune modulation or specific inflammatory process in the urinary tract related to lipid emulsions.
Importance of AA:DHA ratio
Intravenous lipid emulsions are essential for preterm infants in the early postnatal period as these emulsions provide long-chain polyunsaturated fatty acids (LCPUFAs) critical for growth, neurodevelopment, and immune function [3]. The ones most important for preterm infants are DHA and AA. SO-ILEs are predominantly composed of omega-6 fatty acids, particularly LA, which serves as a precursor for arachidonic acid (ARA), whereas SMOF-ILE contains a mixed lipid composition with reduced omega-6 content and increased omega-3 fatty acids, predominantly composed of omega-3 fatty acids, including ALA, EPA, and DHA (Supplementary Table 1).
While omega-3 fatty acids have well-documented anti-inflammatory and neuroprotective effects, maintaining an appropriate balance between DHA and AA is crucial. A nutritional strategy that optimizes the need for both n-6 and n-3 fatty acids will lead to optimal outcomes [19]. AA is essential for brain growth during gestation and early infancy, cell membrane integrity, immune signaling (particularly via eicosanoids), and is the predominant LCPUFA in most human organs [22]. Importantly, DHA and AA share common enzymatic pathways, and an excessive intake of DHA can reduce tissue incorporation or synthesis of AA. This competitive interaction has been demonstrated in animal models, where high-DHA diets were associated with significantly reduced AA concentrations in specific brain regions. Additionally, AA is a precursor to adrenic acid, a fatty acid involved in neural tissue development, underscoring its indispensable role during early brain maturation [22]. Although SMOF-ILE offers a more balanced profile of LCPUFAs compared to SO-ILE, the optimal ratio of AA to DHA in preterm nutrition has yet to be clearly established [19]. This can be one of the reasons why there is conflicting findings between our current study and previous studies [47]. Future research is warranted to better define an ideal lipid emulsion composition that maintains an optimal AA:DHA ratio that closely mimics the physiological supply of fatty acids during fetal development.
Strengths and limitations
A major strength of our retrospective cohort study is the multicentered approach for evaluating both growth outcomes and preterm-related morbidities in infants receiving two different ILE formulations for at least seven consecutive days. The multicenter design offers a more heterogeneous patient population and greater generalizability of our findings. This study also has several limitations. As a retrospective study, it was not possible to control for all potential confounders, such as exposure to antibiotics or postnatal steroids as well as the proportion of mother’s own milk received, which can significantly influence comorbidities and growth. Although there were no significant feeding protocol changes that occurred at either center during the study time periods, the absence of detailed enteral feeding data limits our ability to attribute the results solely to the type of ILE exposure. In addition, the mean duration of ILE exposure in both groups was ~12 days, whereas several of the significant growth outcomes were measured for change between 1 month of age to 36 weeks’ PMA or discharge. Therefore, these growth outcomes can also be influenced by several postnatal factors such as subsequent enteral nutrition practices, illness burden such as (respiratory disease severity and/or infection), and postnatal steroid courses. The observational design of this study limits the ability to establish a direct causal relationship between the initial lipid emulsion exposure and later anthropometric outcomes. Accordingly, the findings related to length and head circumference growth at 36 weeks’ PMA should be considered hypothesis-generating rather than definitive evidence of long-term growth benefit attributable to SO-ILE. Lastly, given the number of primary and secondary outcomes evaluated, the potential for type I error and false-positive findings should be considered, particularly since formal adjustment for multiple comparisons was not performed. Accordingly, these results should be interpreted with caution and require confirmation in future prospective studies.
Conclusion
At 36 weeks’ PMA, SO-ILE was associated with improved length and head circumference growth and lower rates of BPD and urinary infections, without significant differences in PNAC or other major comorbidities. While SMOF-ILE offers a more balanced fatty acid profile, these findings suggest that the higher omega-3 content may not universally translate into improved outcomes in this population. Given the conflicting data in the literature and the implications for optimizing parenteral nutrition in preterm infants, a well-designed multicenter RCT is warranted to better determine the comparative efficacy of SO-ILE versus SMOF-ILE in this vulnerable population. Therefore, based on our study findings and existing literature, SO-ILE remains a reasonable lipid emulsion option for preterm infants until more definitive evidence surrounding benefits of alternative lipid sources is available.
Data availability
All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author, Rita Ryan MD (rita.ryan@uhhospitals.org).
References
Salama GS, Kaabneh MA, Almasaeed MN, Alquran M. Intravenous lipids for preterm infants: a review. Clin Med Insights Pediatr. 2015;9:25–36.
Calder PC. Functional roles of fatty acids and their effects on human health. JPEN J Parenter Enter Nutr. 2015;39:18s–32s.
Martin CR. Fatty acid requirements in preterm infants and their role in health and disease. Clin Perinatol. 2014;41:363–82.
Gramlich L, Ireton-Jones C, Miles JM, Morrison M, Pontes-Arruda A. Essential fatty acid requirements and intravenous lipid emulsions. JPEN J Parenter Enter Nutr. 2019;43:697–707.
Huff KA, Nayak SP, Ahmad I, DiGeronimo R, Hair A, Kim JH, et al. Patterns of lipid-injectable emulsion use in neonatal intensive care units across the United States: a multi-institution survey. J Parenter Enter Nutr. 2023;47:51–8.
Greenberg J, Naik M, Chapman J, Davidson A, Imseis E. Comparison of two lipid emulsions on the incidence of parenteral nutrition associated cholestasis in neonates. J Pediatr Pharm Ther. 2023;28:129–35.
Guthrie G, Burrin D. Impact of parenteral lipid emulsion components on cholestatic liver disease in neonates. Nutrients. 2021;13:508.
Hellström A, Hellström W, Hellgren G, LEHS, Puttonen H, Fyhr IM, et al. Docosahexaenoic acid and arachidonic acid levels are associated with early systemic inflammation in extremely preterm infants. Nutrients. 2020;12:1996.
Martin CR, Dasilva DA, Cluette-Brown JE, Dimonda C, Hamill A, Bhutta AQ, et al. Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbidities. J Pediatr. 2011;159:743–9.e741-2.
FDA Office of Clinical Pharmacology Review. 2022. https://www.fda.gov/media/158295/download#:~:text=Smoflipid%2020%25%20.
Waitzberg DL, Torrinhas RS, Jacintho TM. New parenteral lipid emulsions for clinical use. JPEN J Parenter Enter Nutr. 2006;30:351–67.
Bilal RM, Liu C, Zhao H, Wang Y, Farag MR, Alagawany M, et al. Olive oil: nutritional applications, beneficial health aspects and its prospective application in poultry production. Front Pharm. 2021;12:723040.
Casson C, Nguyen V, Nayak P, Channabasappa N, Berris K, Panczuk J, et al. A comparison of Smoflipid® and Intralipid® in the early management of infants with intestinal failure. J Pediatr Surg. 2020;55:153–7.
Jackson RL, White PZ, Zalla J. SMO flipid vs intralipid 20%: effect of mixed-oil vs soybean-oil emulsion on parenteral nutrition-associated cholestasis in the neonatal population. JPEN J Parenter Enter Nutr. 2021;45:339–46.
Zhang P, Lavoie PM, Lacaze-Masmonteil T, Rhainds M, Marc I. Omega-3 long-chain polyunsaturated fatty acids for extremely preterm infants: a systematic review. Pediatrics. 2014;134:120–34.
Hsiao CC, Lin HC, Chang YJ, Yang SP, Tsao LY, Lee CH, et al. Intravenous fish oil containing lipid emulsion attenuates inflammatory cytokines and the development of bronchopulmonary dysplasia in very premature infants: a double-blind, randomized controlled trial. Clin Nutr. 2019;38:1045–52.
Skouroliakou M, Konstantinou D, Agakidis C, Kaliora A, Kalogeropoulos N, Massara P, et al. Parenteral MCT/ω-3 polyunsaturated fatty acid-enriched intravenous fat emulsion is associated with cytokine and fatty acid profiles consistent with attenuated inflammatory response in preterm neonates: a randomized, double-blind clinical trial. Nutr Clin Pr. 2016;31:235–44.
Wolff J, Cober MP, Huff KA. Essential fatty acid deficiency in parenteral nutrition: historical perspective and modern solutions, a narrative review. Nutr Clin Pract. 2025;40:350–67.
Frazer LC, Martin CR. Parenteral lipid emulsions in the preterm infant: current issues and controversies. Arch Dis Child Fetal Neonatal Ed. 2021;106:676–81.
Rubin D, Laposata M. Cellular interactions between n-6 and n-3 fatty acids: a mass analysis of fatty acid elongation/desaturation, distribution among complex lipids, and conversion to eicosanoids. J Lipid Res. 1992;33:1431–40.
Najm S, Löfqvist C, Hellgren G, Engström E, Lundgren P, Hård AL, et al. Effects of a lipid emulsion containing fish oil on polyunsaturated fatty acid profiles, growth and morbidities in extremely premature infants: a randomized controlled trial. Clin Nutr ESPEN. 2017;20:17–23.
Hadley KB, Ryan AS, Forsyth S, Gautier S, Salem N Jr. The essentiality of arachidonic acid in infant development. Nutrients. 2016;8:216.
Robinson DT, Martin CR. Fatty acid requirements for the preterm infant. Semin Fetal Neonatal Med. 2017;22:8–14.
Uberos J, Jiménez-Montilla S, Molina-Oya M, Nieto-Gómez P, Millan IC. Morbidity outcomes of very low birth weight neonates receiving parenteral nutrition with fish oil enriched lipid emulsion or lipid emulsion with soybean oil: an observational study. Am J Perinatol. 2021;38:952–9.
Choudhary N, Tan K, Malhotra A. Inpatient outcomes of preterm infants receiving ω-3 enriched lipid emulsion (SMOFlipid): an observational study. Eur J Pediatr. 2018;177:723–31.
Costa S, Cocca C, Barone G, Catenazzi P, Gallini F, Maggio L, et al. Growth of head circumference and body length in preterm infants receiving a multicomponent vs a soybean-based lipid emulsion: a randomized controlled trial. JPEN J Parenter Enter Nutr. 2021;45:94–101.
Asfour SS, Alshaikh B, AlMahmoud L, Sumaily HH, Alodhaidan NA, Alkhourmi M, et al. SMO flipid impact on growth and neonatal morbidities in very preterm infants. Nutrients. 2022;14:3952.
Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 2013;13:59.
Harb R, Thomas DW. Conjugated hyperbilirubinemia. Screen Treat older infants Child Pediatr Rev. 2007;28:83–91.
Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. an evidence-based approach. Am J Respir Crit Care Med. 2019;200:751–9.
Holtrop P, Swails T, Riggs T. Hypertriglyceridemia in extremely low birth weight infants receiving lipid emulsions. J Neonatal Perinat Med. 2015;8:133–6.
Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986;33:179–201.
The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123:991–9.
Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92:529–34.
Fenton TR, Elmrayed S, Alshaikh BN. Fenton third-generation growth charts of preterm infants without abnormal fetal growth: a systematic review and meta-analysis. Paediatr Perinat Epidemiol. 2025;39:543–55.
Landau-Crangle E, Rochow N, Fenton TR, Liu K, Ali A, So HY, et al. Individualized postnatal growth trajectories for preterm infants. J Parenter Enter Nutr. 2018;42:1084–92.
Abrams SA, Ernst KD, Weitkamp JH, Mascarenhas M, Anderson-Berry A, Rudolph J, et al. Safety and efficacy of a composite lipid emulsion with fish oil in hospitalized neonates and infants requiring prolonged parenteral nutrition - a randomized, double-blind, multicenter, controlled trial. J Nutr. 2024;154:3615–25.
Costa S, Cocca C, D’Apolito G, De Gisi A, Fattore S, Tataranno ML, et al. Effects of a multicomponent lipid emulsion on brain volumes in extremely low birth weight infants. Am J Perinatol. 2023;41:e1813–9.
Bin-Nun A, Kassirer Y, Mimouni FB, Shchors I, Hammerman C. Head circumference growth is enhanced by SMO flipid in preterm neonates. Am J Perinatol. 2020;37:1130–3.
Al-Mouqdad MM, Alshaikh B, Sumaily HH, Alodhaidan NA, AlMahmoud L, Almotiri AA, et al. Association between SMOFlipid and impaired brain development on term-equivalent age brain magnetic resonance imaging in very preterm infants. BMC Pediatr. 2024;24:686.
Caruggi S, Calandrino A, Corradi B, Battaglini M, Massirio P, Vinci F, et al. Do different lipid emulsions affect brain development? A single-center retrospective analysis. Front Nutr. 2026;13:1723062.
Lavoie J-C, Mohamed I, Nuyt A-M, Elremaly W, Rouleau T. Impact of SMOF lipid on pulmonary alveolar development in newborn guinea pigs. J Parenter Enter Nutr. 2018;42:1314–21.
Dang D, Gao Z, Zhang C, Mu X, Lv X, Wu H. Effect of enteral supplementation of DHA with or without ARA in preterm infants: a meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2026;111:F27–33.
Wackernagel D, Nilsson AK, Sjöbom U, Hellström A, Klevebro S, Hansen-Pupp I. Enteral supplementation with arachidonic and docosahexaenoic acid and pulmonary outcome in extremely preterm infants. Prostaglandins Leukot Essent Fatty Acids. 2024;201:102613.
Correani A, Dell’Orto V, Nobile S, Antognoli L, Marchionni P, Giretti I, et al. Oxygen saturation to fraction of inspired oxygen ratio in preterm infants on routine parenteral nutrition with conventional or fish oil containing lipid emulsions. Pediatr Pulmonol. 2020;55:2377–82.
Repa A, Binder C, Thanhaeuser M, Kreissl A, Pablik E, Huber-Dangl M, et al. A mixed lipid emulsion for prevention of parenteral nutrition associated cholestasis in extremely low birth weight infants: a randomized clinical trial. J Pediatr. 2018;194:87–93.e81.
Kapoor V, Malviya MN, Soll R. Lipid emulsions for parenterally fed preterm infants. Cochrane Database Syst Rev. 2019;6:Cd013163.
Bodur M, Yilmaz B, Ağagündüz D, Ozogul Y. Immunomodulatory effects of omega-3 fatty acids: mechanistic insights and health implications. Mol Nutr Food Res. 2025;69:e202400752.
Luu N-T, Madden J, Calder PC, Grimble RF, Shearman CP, Chan T, et al. Dietary supplementation with fish oil modifies the ability of human monocytes to induce an inflammatory response. J Nutr. 2007;137:2769–74.
Mayer K, Merfels M, Muhly-Reinholz M, Gokorsch S, Rosseau S, Lohmeyer J, et al. ω-3 Fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am J Physiol Heart Circ Physiol. 2002;283:H811–8.
Hsieh AT, Anthony JC, Diersen-Schade DA, Rumsey SC, Lawrence P, Li C, et al. The influence of moderate and high dietary long chain polyunsaturated fatty acids (LCPUFA) on baboon neonate tissue fatty acids. Pediatr Res. 2007;61:537–45.
Author information
Authors and Affiliations
Department of Pharmacy, Cleveland Clinic Children’s Hospital, Cleveland, OH, USA
Alexyss Guy
Department of Pediatrics, Division of Neonatal-Perinatal Medicine, Cohen Children’s Medical Center, Northwell Health, New Hyde Park, NY, USA
Austin Han
Department of Pharmacy, Mount Sinai Hospital, New York, NY, USA
Diana Kwiatkowski
Department of Pharmacy, Rainbow Babies and Children’s Hospital, Cleveland, OH, USA
Anna C. Felmer, Christina Gerber & Jaime Marasch
Department of Pediatrics, Division of Neonatology, NYU Langone Hospital - Long Island, NYU Grossman Long Island School of Medicine, Mineola, NY, USA
Rachel H. Lee, Amrita Nayak, Rebecca Goodman & Zeyar T. Htun
Department of Pharmacy, NYU Langone Hospital - Long Island, Mineola, NY, USA
Rachel H. Lee
Biostats Inc, East Canton, OH, USA
Dave Gothard
Division of Neonatology, Department of Pediatrics, UH Rainbow Babies and Children’s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
Rita M. Ryan
Authors
- Alexyss Guy
- Austin Han
- Diana Kwiatkowski
- Anna C. Felmer
- Christina Gerber
- Rachel H. Lee
- Amrita Nayak
- Rebecca Goodman
- Dave Gothard
- Rita M. Ryan
- Jaime Marasch
- Zeyar T. Htun
Contributions
ZTH, RG, JM, AF, RG, AN, and RR conceptualized and designed the study. AG, AH, DK collected the clinical data and contributed to the initial draft of the manuscript. ZTH, AF, CG, RL, AN, RG, RR, JM critically reviewed and edited the manuscript. ZTH and JM supervised the study and data collection. DG provided statistical analysis. ZTH revised the manuscript for final submission. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Corresponding author
Correspondence to Rita M. Ryan.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
All methods were performed in accordance with the relevant guidelines and regulations of respective IRB boards from NYU Langone and University Hospitals. No informed consent was necessary to be obtained; the study protocol was reviewed and approved as exempt by the institutional review boards of both participating institutions – NYU IRB protocol s24-00105 and RBC protocol STUDY20241092.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Guy, A., Han, A., Kwiatkowski, D. et al. Comparison of growth and morbidity outcomes in preterm infants using two different intravenous lipid emulsions. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02865-w
Received: 27 February 2026
Revised: 10 July 2026
Accepted: 31 July 2026
Published: 08 October 2026
Version of record: 08 October 2026
DOI: https://doi.org/10.1038/s41372-026-02865-w
来源:Nature 健康护理主题 · nature.com